CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab

NCT02634970 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Wet Age-related Macular Degeneration (Wet AMD)

Interventions

DRUG: Ranibizumab

Sponsor

Novartis Pharmaceuticals